We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

13 hedge funds and large institutions have $26.8M invested in Verona Pharma in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

1.43% less ownership

Funds ownership: 7% → 5.57% (-1.4%)

24% less funds holding

Funds holding: 17 → 13 (-4)

29% less capital invested

Capital invested by funds: $37.6M → $26.8M (-$10.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
13
Holders Change
-4
Holders Change %
-23.53%
% of All Funds
0.28%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
–
Increased
2
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WS
Wedbush Securities
California
+$26.8K
2
IWM
IHT Wealth Management
Illinois
+$14K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$7.61M
2
Renaissance Technologies
Renaissance Technologies
New York
-$53K
3
Deutsche Bank
Deutsche Bank
Germany
-$44.2K
4
OSNBOA
Old Second National Bank of Aurora
Illinois
-$8K
5
UBS Group
UBS Group
Switzerland
-$1.22K

VRNA Hedge Fund Activity: Q3 2019 in Review

13 of the 4,565 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q3 2019, worth a combined $26.8M — down 29% from $37.6M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of VRNA and 0 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Wedbush Securities, adding an estimated $26.8K. The largest seller was Vivo Capital, exiting entirely with an estimated $7.61M sold.

  • 13 institutional investors held Verona Pharma (VRNA) as of Q3 2019, down from 17 in Q2 2019.
  • Funds reported $26.8M of Verona Pharma stock for Q3 2019, down 29% quarter-over-quarter.
  • 0 funds opened new Verona Pharma positions in Q3 2019 and 4 closed out, a net change of -4 holders.
  • The largest Verona Pharma buyer in Q3 2019 was Wedbush Securities, an estimated $26.8K added.
  • The largest Verona Pharma seller in Q3 2019 was Vivo Capital, an estimated $7.61M sold.

Based on aggregated 13F filings for Q3 2019.